The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
- 30 July 2025
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 27 (1) , 1-12
Abstract
Purpose of Review This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM). Recent Findings Originally developed for glycemic control in T2DM, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now being utilized for a range of additional diseases and conditions. Strong evidence supports their efficacy in inducing clinically meaningful weight loss in individuals with overweight or obesity. Further studies have demonstrated cardiovascular benefits, kidney-protective effects, and therapeutic potential in obesity-related conditions such as obstructive sleep apnea and metabolic-associated steatotic liver disease. Emerging data also suggest possible roles in treating substance use disorders, including alcohol and nicotine dependence, though findings remain preliminary and variable. Despite these promising developments, GLP-1RAs are associated with side effects and high costs, contributing to variability in patient access. Summary The therapeutic scope of GLP-1 receptor agonists extends beyond diabetes to multiple other conditions. Broader adoption requires careful evaluation of safety, cost, and evidence for less-established indications.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 95 references indexed in Scilit:
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2025
- The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic ReviewCurrent Treatment Options in Psychiatry, 2024
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If UnaffordableJAMA, 2024
- Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathyDiabetologia, 2024
- The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled TrialsThe American Journal of Clinical Nutrition, 2023
- Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCTArchives of Gynecology and Obstetrics, 2022
- Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysisJournal of Endocrinological Investigation, 2019
- The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical TrialJournal of Bone and Mineral Research, 2017
- Effects of GLP-1 on appetite and weightReviews in Endocrine and Metabolic Disorders, 2014